The combination of dyclonine and SAS cooperatively inhibited the growth of HNSCC and gastric cancer, both of which highly express ALDH3A1 and are resistant to SAS monotherapy. The gene discussed is ALDH3A1; the disease is head and neck squamous cell carcinoma.